MMP patients have a significantly increased risk of SCC, BCC, and NMSC, particularly with severe disease. The study analyzed data from over 117 million individuals, using propensity-score matching for ...
Aperture Therapeutics is advancing APRTX-003, an RNA-based antisense therapy targeting MMP9, as a potential ALS treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback